A Novel Class of Synthetic Receptors to Empower the Age of mRNA Therapies
一类新型合成受体将推动 mRNA 治疗时代的到来
基本信息
- 批准号:10687517
- 负责人:
- 金额:$ 135.08万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-19 至 2026-09-18
- 项目状态:未结题
- 来源:
- 关键词:AblationAdoptive Cell TransfersAdverse effectsAgeAntigensBasic ScienceCAR T cell therapyCell ExtractsCell physiologyCellsComputer SimulationCuesDNADimerizationDiseaseDopamineEngineeringEventExposure toFibroblastsGeneral PopulationGenomeHalf-LifeImmuneLigandsLogicLogisticsMalignant NeoplasmsMediatingMessenger RNAModalityMutationMyocardial InfarctionNeuronsOutputPatientsPopulationPrecision therapeuticsProcessProteinsPublic HealthRNAResearch PersonnelRiskSafetySignal TransductionSurfaceT-LymphocyteTissue EngineeringTranscriptVaccinationVaccinescellular engineeringchimeric antigen receptorchimeric antigen receptor T cellscoronavirus diseasecostcytokinedelivery vehicledesignempowermentextracellularimmunoengineeringimprovedin vivomRNA deliverymanufacturenotch proteinnovelnovel therapeuticsreceptorresponsesenescencetoolvaccine efficacy
项目摘要
Abstract
The COVID vaccination campaigns have highlighted the promise of mRNA-mediated delivery as a novel
therapeutic modality. One particular application is adoptive cell therapy, where immune cells are equipped with
novel functions to treat diseases, e.g., expressing chimeric antigen receptors (CARs) in T cells to ablate cancer
and other undesirable cells. Compared to DNA-based engineering of immune cells, mRNA has several
advantages as a delivery vector, especially its superior safety profile, because it eliminates the risk of randomly
inserting into the host genome and causing mutations, and its short half-life mitigates long-term adverse effects
due to the persistence of the engineered cellular function. Instead of extracting cells from the patient, engineering
them ex vivo, and then reinducing them, researchers have even directly delivered CAR-encoding mRNAs and
created functional CAR T cells in vivo. This is appealing because it has the potential to make adoptive cell
therapy accessible to the general public, its logistics almost as straightforward as manufacturing, distributing,
and administering vaccine shots, in contrast to the costly ex vivo engineering process that will be limited to the
privileged few.
Despite the great potential of mRNA-mediated adoptive cell therapy, there remains a critical need for
tools that enhance targeting precision. It is very rare for a single surface marker, targeted by CAR, to
unambiguously identify one target cell population. Therefore, “on-target/off-caner” killing is a major concern for
CAR T cell therapies against cancer, and the same concern also applies to scenarios of ablating other cells,
such as active fibroblasts in heart infarction or senescent cells. One elegant solution is synthetic receptors, most
notably synthetic Notch, that detect a second marker and express CAR in response, effectively forming AND
logic, where target cells are only killed when both inputs to the synthetic receptor and CAR are present. However,
to our knowledge, all existing synthetic modular, programmable receptors operate at the DNA level, and are
therefore incompatible with mRNA-mediated delivery.
Here we design and demonstrate the feasibility of a first-in-class synthetic modular receptor that operate
at the RNA level. It converts ligand-induced dimerization events into the expression of arbitrary output proteins.
Through extensive computational simulation and experimental optimization, we will expand the input/output
repertoire of this receptor, establish its design principle, enable its encoding on single transcripts and delivery by
mRNA, and take first steps towards improving the precision of ablating active fibroblasts to treat heart infarction.
The impact of such novel receptors is beyond adoptive cell therapy. For example, they can facilitate basic
research by recording cells’ (e.g., neurons) exposure to specific signals (e.g., dopamine). They will benefit a
variety of other biomedical applications too, from expressing antigens or cytokines in response to extracellular
cues to enhance vaccine efficacy, to generating novel sense-and-respond capabilities for tissue engineering.
摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Xiaojing J Gao其他文献
Xiaojing J Gao的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Xiaojing J Gao', 18)}}的其他基金
Program the Immune System against RAS-driven Cancer
对免疫系统进行编程以对抗 RAS 驱动的癌症
- 批准号:
10612257 - 财政年份:2023
- 资助金额:
$ 135.08万 - 项目类别:
Cancer Classifiers Based on RNA Sensors in Living Cells
基于活细胞中 RNA 传感器的癌症分类器
- 批准号:
10570559 - 财政年份:2022
- 资助金额:
$ 135.08万 - 项目类别:
Cancer Classifiers Based on RNA Sensors in Living Cells
基于活细胞中 RNA 传感器的癌症分类器
- 批准号:
10707194 - 财政年份:2022
- 资助金额:
$ 135.08万 - 项目类别:
Synthetic DNA-free Circuits for “Scarless” Programming of Mammalian Cells
用于哺乳动物细胞“无痕”编程的合成无 DNA 电路
- 批准号:
10115864 - 财政年份:2020
- 资助金额:
$ 135.08万 - 项目类别:
Synthetic DNA-free Circuits for “Scarless” Programming of Mammalian Cells
用于哺乳动物细胞“无痕”编程的合成无 DNA 电路
- 批准号:
10379933 - 财政年份:2020
- 资助金额:
$ 135.08万 - 项目类别: